Compare Abeona Therapeutics Inc (ABEO) vs AMETEK, Inc. (AME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs AMETEK, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while AMETEK, Inc. trades at $228.58 (market cap $53.11B). The key difference: AMETEK, Inc. is far larger — about 142.3× Abeona Therapeutics Inc's market cap, and AMETEK, Inc. pays a 0.59% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AME | |
|---|---|---|
Market Cap | $373.32M | $53.11B |
Sector | Health | Industrials |
52-Week High | $7.23 | $241.94 |
52-Week Low | $4.17 | $176.44 |
Enterprise Value | $228.22M | $54.80B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AME trades at $231.70, down 1.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $263.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.97 exceeding expectations. Revenue grew to $7.40 billion in 2025, and net income margin improved to 20.11%. Recent acquisitions, including First Aviation Services and the Indicor Instrumentation group for $5 billion, aim to expand its aerospace and industrial technology footprint.
The outlook for AME is positive, supported by earnings momentum, strategic acquisitions, and solid profitability. Risks include integration challenges from large acquisitions and elevated valuation multiples, such as a P/E of 35.82. With no sell ratings from analysts and institutional backing, the stock presents a growth opportunity, though investors should monitor execution on acquisition synergies and macroeconomic conditions affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →
